Prakiraan wutah bathi resik saben saham kanggo taun ngarep Cardiff Oncology Corp (CRDF)

Logo korporat perusahaan Cardiff Oncology (CRDF)

High patent barriers and R&D costs limit entry into the targeted therapy niche. Cardiff Oncology, Inc. (CRDF) is developing onvansertib, whose compatibility with standards of care promises sustainable margins. However, the lack of commercial products leaves the company dependent on investment. The consensus estimate for net profit growth rates reflects current dynamics, where the actual value is -10.20.

Cardiff Oncology Corp (CRDF): Prakiraan wutah bathi resik saben saham kanggo taun ngarep saka 04.07.2022 nganti 16.11.2026

Ringkesan rincian data analitis Cardiff Oncology, Inc. (CRDF)

- rega saham lan konsensus proyeksi valuasi:
Analisis fundamental perusahaan:Cardiff Oncology Inc.
Produk dadi Cardiff Oncology Corp

The investment attractiveness of Cardiff Oncology, Inc. (CRDF) is based on the success of its biotechnological developments. This metric calculates the percentage change in expected earnings per share, reflecting the analysts' consensus forecast for future profitability. The one-year forward EPS growth trend allows for an assessment of the impact of geopolitical risks and regulatory barriers on the pace of drug commercialization. A stable trend in this indicator confirms the company's fundamental resilience to external shocks.

Analisis pesaing Cardiff Oncology, Inc.

INCY (incyte.com) - Prakiraan wutah bathi kanggo taun ngarep|Prakiraan wutah bathi resik saben saham ing taun ngarep hutch-med.com HCM|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Nuvation Corp (NUVB)|DAWN - Prakiraan wutah bathi resik saben saham ing taun ngarep|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Monopar Pharma MNPR|Inhibrx Corp - Prakiraan wutah bathi resik saben saham kanggo taun ngarep|IMAB - Prakiraan wutah bathi resik saben saham kanggo taun ngarep|Prakiraan wutah bathi resik saben saham ing taun ngarep Fennec Pharmaceuticals|HRTX: Prakiraan wutah bathi kanggo taun ngarep|Prakiraan wutah bathi resik saben siji saham kanggo taun ngarep Nuvectis NVCT|Prakiraan wutah bathi saben saham kanggo taun ngarep CHRS|Prakiraan wutah bathi resik saben saham ing taun ngarep Corbus Pharmaceuticals CRBP|Prakiraan wutah bathi saben saham kanggo taun ngarep BYSI (BeyondSpring Inc.)|BCAB (BioAtla Corp) - Dinamika bathi saben saham sing diarepake ing taun ngarep|Lixte Biotechnology - Prakiraan wutah bathi saben saham kanggo taun ngarep|Proyeksi tambahing bathi saben saham ing taun ngarep CTXR (Citius Pharma)|Cellectar - Prakiraan wutah bathi kanggo taun ngarep|Dinamika bathi saben saham sing diarepake ing taun ngarep BLRX (BioLineRx Corp)|CANF: Prakiraan wutah bathi kanggo taun ngarep|Prakiraan wutah bathi resik saben saham ing taun ngarep Aprea (APRE)|Prakiraan wutah bathi resik saben saham kanggo taun ngarep kaziatherapeutics.com|SLXN: Dinamika bathi saben saham sing diarepake ing taun ngarep|Prakiraan wutah bathi kanggo taun ngarep NCNA|Prakiraan wutah bathi kanggo taun ngarep Chimerix Inc (CMRX)|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Cyclacel Pharmaceuticals Inc. CYCC|GTHX (g1therapeutics.com) - Prakiraan owah-owahan bathi resik saben saham kanggo taun ngarep|KRON: Prakiraan wutah bathi saben saham kanggo taun ngarep|Prakiraan wutah bathi resik saben saham ing taun ngarep Kintara Therapeutics Inc|oncternal.com (ONCT) - Prakiraan wutah bathi resik saben saham kanggo taun ngarep|Prakiraan owah-owahan bathi resik saben saham kanggo taun ngarep PRTG (Portage Biotech Corp)